Rhumbline Advisers reduced its stake in shares of Qiagen NV (NASDAQ:QGEN) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 208,563 shares of the company’s stock after selling 2,288 shares during the quarter. Rhumbline Advisers owned approximately 0.09% of Qiagen worth $6,451,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Stevens Capital Management LP bought a new position in Qiagen in the 3rd quarter worth about $1,120,000. Sei Investments Co. boosted its stake in Qiagen by 37.5% in the 3rd quarter. Sei Investments Co. now owns 242,613 shares of the company’s stock worth $7,642,000 after purchasing an additional 66,194 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Qiagen by 1.6% during the 3rd quarter. New York State Common Retirement Fund now owns 501,947 shares of the company’s stock valued at $15,811,000 after acquiring an additional 8,000 shares during the period. Los Angeles Capital Management & Equity Research Inc. lifted its stake in Qiagen by 16.5% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 633,300 shares of the company’s stock valued at $19,949,000 after acquiring an additional 89,491 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in Qiagen by 1.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,289,162 shares of the company’s stock valued at $40,608,000 after acquiring an additional 22,587 shares during the period. 62.23% of the stock is currently owned by institutional investors and hedge funds.
Qiagen NV (NASDAQ:QGEN) traded down $0.35 on Wednesday, reaching $33.65. The company’s stock had a trading volume of 814,556 shares, compared to its average volume of 1,196,505. Qiagen NV has a 52 week low of $27.74 and a 52 week high of $36.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.59. The stock has a market capitalization of $7,980.00, a price-to-earnings ratio of -338.40, a PEG ratio of 1.93 and a beta of 0.98.
Qiagen (NASDAQ:QGEN) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.43 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.01. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The business had revenue of $396.86 million for the quarter, compared to analyst estimates of $394.48 million. research analysts predict that Qiagen NV will post 1.34 earnings per share for the current fiscal year.
Qiagen announced that its board has approved a share buyback program on Wednesday, January 31st that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to buy shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.
QGEN has been the topic of several recent research reports. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research note on Friday, December 1st. Zacks Investment Research lowered shares of Qiagen from a “hold” rating to a “sell” rating in a report on Monday, December 11th. Commerzbank reissued a “buy” rating on shares of Qiagen in a report on Tuesday, December 12th. DZ Bank reaffirmed a “neutral” rating on shares of Qiagen in a report on Tuesday, December 19th. Finally, BidaskClub raised shares of Qiagen from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Qiagen has a consensus rating of “Hold” and an average price target of $35.33.
WARNING: “Qiagen NV (NASDAQ:QGEN) Shares Sold by Rhumbline Advisers” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/03/14/rhumbline-advisers-decreases-holdings-in-qiagen-nv-qgen.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.